Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.05 USD
Change Today +0.004 / 8.00%
Volume 44.0K
ICOTF On Other Exchanges
Symbol
Exchange
Venture
OTC US
Frankfurt
As of 8:10 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

ico therapeutics inc (ICOTF) Snapshot

Open
$0.05
Previous Close
$0.05
Day High
$0.05
Day Low
$0.05
52 Week High
06/2/14 - $0.34
52 Week Low
12/26/14 - $0.02
Market Cap
4.6M
Average Volume 10 Days
25.6K
EPS TTM
--
Shares Outstanding
84.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ICO THERAPEUTICS INC (ICOTF)

Related News

No related news articles were found.

ico therapeutics inc (ICOTF) Related Businessweek News

View More BusinessWeek News

ico therapeutics inc (ICOTF) Details

iCo Therapeutics Inc., a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-007, an antisense inhibitor that is in Phase II clinical trial for the treatment of diabetic macular edema; and iCo-008 (Bertilimumab), a human immunoglobulin monoclonal antibody, which is in Phase I clinical trial to treat sight threatening ocular allergies and various systemic indications. The company also develops Oral Amphotericin B Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections in immune-compromised patients, such as in HIV/AIDS, cancer, transplant recipients, diabetics, etc., as well as certain parasitical infections. iCo Therapeutics Inc. has partnership arrangements with Isis Pharmaceuticals, Inc.; MedImmune Limited; Immune Pharmaceuticals Inc.; AstraZeneca; and the University of British Columbia. iCo Therapeutics Inc. was founded in 2005 and is headquartered in Vancouver, Canada.

5 Employees
Last Reported Date: 04/27/15
Founded in 2005

ico therapeutics inc (ICOTF) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: C$234.7K
Chief Financial Officer and Corporate Secreta...
Total Annual Compensation: C$140.0K
Chief Medical Officer
Total Annual Compensation: C$160.0K
Compensation as of Fiscal Year 2013.

ico therapeutics inc (ICOTF) Key Developments

iCo Therapeutics Inc. Reports Financial Results for the Year Ended December 31, 2014

iCo Therapeutics Inc. reported financial results for the year ended December 31, 2014. The company incurred a total comprehensive loss of CAD,079,657 for the year ended December 31, 2014 compared to a total loss of CAD 5,918,965 for the year ended 2013, representing a decrease of CAD 3,839,308. The decrease in its net and comprehensive loss was principally caused by a reduction of clinical trial costs associated with the iDEAL study.

iCo Therapeutics Seeks Acquisitions

iCo Therapeutics Inc. (TSXV:ICO) is looking for acquisitions. Andrew Rae, President and Chief Executive Officer of iCo Therapeutics states, "We remain committed to our oral Amphotericin B clinical study plans and continue to assess complimentary assets which the Company may consider in-licensing or acquiring."

iCo Therapeutics Inc., Annual General Meeting, May 22, 2015

iCo Therapeutics Inc., Annual General Meeting, May 22, 2015. Location: Blake, Cassels & Graydon LLP.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ICOTF:US $0.05 USD +0.004

ICOTF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ICOTF.
View Industry Companies
 

Industry Analysis

ICOTF

Industry Average

Valuation ICOTF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ICO THERAPEUTICS INC, please visit www.icotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.